

Cancer Immunol Immunother (2009) 58:831–841  
DOI 10.1007/s00262-008-0619-x

REVIEW

# Targets for active immunotherapy against pediatric solid tumors

J. F. M. Jacobs · P. G. Coulie · C. G. Figdor ·  
G. J. Adema · I. J. M. de Vries · P. M. Hoogerbrugge

Received: 8 July 2008 / Accepted: 22 October 2008 / Published online: 14 November 2008  
© The Author(s) 2008. This article is published with open access at Springerlink.com

**Abstract** The potential role of antibodies and T lymphocytes in the eradication of cancer has been demonstrated in numerous animal models and clinical trials. In the last decennia new strategies have been developed for the use of tumor-specific T cells and antibodies in cancer therapy. Effective anti-tumor immunotherapy requires the identification of suitable target antigens. The expression of tumor-specific antigens has been extensively studied for most types of adult tumors. Pediatric patients should be excellent candidates for immunotherapy since their immune system is more potent and flexible as compared to that of adults. So far, these patients do not benefit enough from the progresses in cancer immunotherapy, and one of the reasons is the paucity of tumor-specific antigens identified on pediatric tumors. In this review we discuss the current status of cancer immunotherapy in children, focusing on the identification of tumor-specific antigens on pediatric solid tumors.

**Keywords** Antigen · Cancer · Immunotherapy · Pediatrics

---

J. F. M. Jacobs · I. J. M. de Vries · P. M. Hoogerbrugge  
Department of Pediatric Hemato-oncology,  
Radboud University Medical Centre Nijmegen,  
Nijmegen, The Netherlands  
e-mail: H.Jacobs@cukz.umcn.nl

P. G. Coulie  
De Duve Institute, Université Catholique de Louvain,  
Brussels, Belgium

J. F. M. Jacobs · C. G. Figdor · G. J. Adema · I. J. M. de Vries (✉)  
Department of Tumor Immunology,  
Nijmegen Centre for Molecular Life Sciences/278 TIL,  
Post Box 9101, 6500 HB Nijmegen, The Netherlands  
e-mail: J.DeVries@ncmls.ru.nl

## Introduction

Despite major advances in the treatment of childhood malignancies, cancer remains in the developed world the second most common cause of death for children >1 year of age [76]. Children and adolescents with primary multifocal, refractory, or relapsed malignant solid tumors still have a poor prognosis. Moreover, most cancer therapies are associated with significant toxicity leading to long-term morbidity and an increased second malignancy rate [75, 135]. Therefore, new treatment strategies are warranted. One of them is immunotherapy, in which the patient's own immune system is mobilized to fight the cancer in a specific way, thereby causing only mild toxicity [101].

## The immune system can reject tumors

Early studies in mice showed that the immune system can recognize and reject tumors [39]. Numerous mouse tumor models have been developed to identify which part of the immune system is responsible for the eradication of tumors. These studies indicate that both CD8<sup>+</sup> and CD4<sup>+</sup> T cells play a critical role in tumor rejection or in inhibition of tumor growth [13]. The cytolytic activity of CD8<sup>+</sup> T cells exerts a direct anti-tumor effect [66]. CD4<sup>+</sup> T cells participate through the activation and maintenance of CD8<sup>+</sup> T cells and the recruitment of inflammatory cells such as macrophages, granulocytes, natural killer (NK) cells, and B cells [24, 47, 51, 93, 131].

Tumor-infiltrating immune cells have frequently been observed in a wide variety of pediatric tumors [103, 125]. Tumor infiltration of lymphocytes is generally associated with a more favorable prognosis and occasionally tumor regression [34, 119]. Another element is the observation

that immunosuppressed patients, such as graft recipients, are at higher risk to develop cancer [36, 89]. Initial studies have consistently shown a role of the immune system in the prevention of virally induced cancers in adults such as Kaposi's sarcoma (linked with human herpes virus 8), cervix carcinoma (human papilloma virus), and hepatocellular carcinoma (hepatitis B and C) [96] but also in children with certain lymphomas (induced by the Epstein-Barr virus) [42, 114]. These data suggest that the immune system plays an important role in preventing or controlling malignancy in both adults and children. In spite of the blood-brain-barrier and lack of conventional lymphatics in the brain, there is accumulating evidence that even brain tumors can cause immune activation [10, 72, 99].


### Immunotherapy strategies in pediatric cancer patients

Immunotherapy can be defined as any approach that seeks to mobilize or manipulate the immune system of a patient for therapeutic benefit (Fig. 1) [61, 116]. Clinical experience of immunotherapy in the pediatric oncological

setting has been gained in treating hematologic malignancies with allogeneic bone marrow transplantations and infusions of donor lymphocytes to generate graft versus leukemia responses [98]. Other clinical trials for pediatric patients have involved general immunostimulation with cytokines such as IL-2, TNF- $\alpha$ , and IFN- $\alpha$ , as adjuvant therapies to eradicate minimal residual disease [62, 112, 123, 133]. Immunotherapeutic therapies targeting identified tumor-associated antigens are discussed in the following.

### Antibodies

The identification of tumor-specific cell-surface molecules opened the possibility for antibody-mediated passive immunotherapy. Antibodies (Ab) against tumor-associated antigens can induce complement dependent cytotoxicity (CDC) and Ab-dependent cell-mediated cytotoxicity (ADCC) [70]. Promising pediatric clinical phase I trials have been described using monoclonal Ab against gangliosides, which are highly expressed in neuroblastoma and osteosarcoma [40, 87, 88, 128]. Tumor-specific Ab



**Fig. 1** Immunotherapeutic strategies applied in pediatric clinical trials. *A* Administration of tumor antigens either directly into the body or loaded onto APC. The TAAs are presented by the APC to lymphocytes in secondary lymphoid organs to initiate a tumor-specific immune response. *B* Non-specific stimulation of the immune response by cytokines, for example IL-2, TNF- $\alpha$  and IFN- $\alpha$  and GM-CSF which induces T cell proliferation. *C* Adoptive transfer of donor lymphocytes or natural killer cells for complete eradication of leukemic cells

following allogeneic transplantation. *D* Monoclonal antibodies (mAb) that bind specifically to cancer cells can induce an immune response. Alternatively, mAb can be modified for targeted delivery of a toxin, radioisotope, cytokine, or other active conjugate. *TAA* tumor-associated antigens, *APC* antigen-presenting cell, *PBL* peripheral blood lymphocyte, *CDC* complement dependent cytotoxicity, *ADCC* antibody dependent cell-mediated cytotoxicity

conjugated to toxins are under investigation as targeted drug-vehicles for embryonal tumors [86, 105].

#### Adoptive cellular immunotherapy

Reconstituting or increasing cellular immunity can be achieved through the infusion of tumor-specific T cells. Autologous CD4<sup>+</sup> or CD8<sup>+</sup> T cells can be manipulated *ex vivo* in various ways to obtain high numbers of clinical grade tumor-specific T cells [23]. The therapeutic effect of infused tumor-specific T cells depends on the viability of the cells, their homing to the tumor, and their ability to kill within the tumor microenvironment.

Another aspect is the renewed appreciation of the role of the innate immune system. Immune-mediated tumor lysis is the result of a combined action of adaptive and innate immunity, in which NK cells are important effector cells. NK cell activation is regulated by a balance between signals mediated through activating receptors such as NKG2D and inhibitory receptors such as killer immunoglobulin-like receptors (KIRs). Upon cellular transformation in tumor cells, MHC class I ligands for inhibitory receptors are often downregulated and ligands for activating NK cell receptors are upregulated on the tumor cell. Together, these events can shift the balance toward NK-mediated tumor-cell killing [78]. Next to the direct cytotoxic effect on tumor cells, NK cells produce type I interferons that create a proinflammatory tumor microenvironment [106, 113]. Clinical studies on adoptive transfer of NK cells in adults have shown that NK cells can have a role in the treatment of selected malignancies [84]. Adoptive transfer of NK cells in pediatric patients with leukemia is feasible [68]. Ongoing clinical studies further investigate NK cell-mediated immunotherapy for pediatric patients with leukemia or neuroblastoma (<http://www.clinicaltrials.gov>).

#### In vivo induction of tumor-specific lymphocytes

The advantage of active immunization over adoptive transfer is the possibility of inducing memory T cells that can control tumor relapse [37]. On the basis of the successes of attenuated pathogen vaccines and owing to the initial lack of defined tumor antigens, the first active immunizations were carried out with whole tumor cells that were previously irradiated or otherwise inactivated [134]. In children, most of the clinical experience using whole tumor cell vaccines is obtained with neuroblastoma patients. In these trials, the neuroblastoma cells are (gene-) modified to express various co-stimulatory molecules or cytokines to increase their immunogenicity [9, 16, 107].

When tumor-associated antigens are identified, therapeutic vaccination can involve the administration of the antigen either as a whole recombinant protein or as

antigenic peptides presented by HLA class I or class II molecules. One clinical trial reports on using chimeric antigenic peptides encoded by translocated genes expressed in Ewing's sarcoma and rhabdomyosarcoma [26]. Another strategy is the administration of autologous antigen-presenting cells, such as dendritic cells, loaded with defined tumor antigens or with tumor cell lysates. We reported that clinical grade dendritic cells can be cultured from blood monocytes of pediatric cancer patients [55]. Others have reported that such dendritic cells can induce tumor-specific T cells that can cause regression of high-risk malignancies in pediatric patients [19, 29, 30, 43].

Advances in gene transfer technology have added new possibilities to optimize vaccine preparation [74, 94]. These include transferring genes encoding pro-inflammatory proteins to tumor cells and transferring tumor antigen-encoding genes into professional antigen-presenting cells. Tumor cells can be engineered to express MHC class I and class II, costimulatory molecules, or cytokines, and used as vaccines. Several gene therapy applications to induce antitumor immunity have been reported for pediatric cancer patients in preliminary phase I studies [9].

Current research also focuses on vaccinating directly with antigen-encoding DNA. Studies in animal models have demonstrated the feasibility of utilizing DNA vaccines to elicit protective cellular and humoral antitumor immune responses [95]. In humans, DNA vaccines are being tested in phase I to III clinical trials for cervical cancer, melanoma, renal cell carcinoma, and prostate cancer [80]. Preliminary results confirm the safety and immunogenicity of these vaccines. DNA vaccinations have not been studied in pediatric patients. However, first steps are being taken with murine studies showing that DNA-vaccination is potentially effective to treat neuroblastoma and prevent neuroblastoma metastases [79, 97].

#### Tumor-associated antigens

One of the reasons for the paucity of clinical trials of therapeutic anti-cancer vaccination in children is the lack of information about the expression of tumor-specific antigens on many pediatric tumors. In the second part of this review we will summarize the current data on the expression of tumor antigens recognized by T cells on a selection of the most common solid pediatric tumors.

Tumor antigens that can be recognized by T lymphocytes are complexes of HLA class I or class II molecules presenting small antigenic peptides. The antigens can be classified into four major groups, based on the pattern of expression of the genes encoding the antigenic peptide [14, 90].

### Antigens resulting from mutations or translocations

These antigens are encoded by genes that are mutated in tumor cells as compared to the normal cells of the patient; the antigens can therefore be considered strictly tumor-specific. The mutations can be point mutations, or translocations, in genes that are expressed ubiquitously. The mutation affects a coding region of the gene, and antigenic peptides contain mutated residues or straddle the junction of chimeric proteins encoded by translocated genes.

### Antigens encoded by cancer-germline genes

Cancer-germline genes are expressed in different types of human tumors. They are not expressed in normal tissues with the exception of male germline cells which do not express HLA molecules and therefore cannot present antigenic peptides to T cells [115]. For this reason the antigens encoded by cancer-germline genes are strictly tumor-specific.

### Differentiation antigens


Differentiation antigens are encoded by lineage-specific genes that are expressed in tumor cells as well as in the normal cells from which the tumor arises. The natural tolerance to these antigens is not complete, and the induction of an immune response against differentiation antigens is possible [35].

### Antigens encoded by genes that are overexpressed in tumors

This last group of tumor antigens is encoded by genes that are overexpressed in tumors as compared to normal tissues. Some oncogenes are expressed in normal tissues at a low level and overexpressed in several tumors [17, 38]. Since both differentiation antigens and overexpressed antigens are expressed in normal tissues, autoimmunity can be a side effect when these antigens are used as immunotherapeutic target.

### T cell defined antigens in pediatric solid tumors

For usefulness in immunotherapy, an antigen has to meet two important criteria. It has to be expressed by the tumor of the patient, and it has to be immunogenic. These criteria can be tested with gene/protein expression and lymphocyte recognition/tumor lysis assays (Fig. 2). For an effective cellular immune response, the tumor-specific antigen must be processed into peptides and presented on HLA molecules. Many tumor-associated antigens and epitopes have been



**Fig. 2** In vitro assays to assess target suitability. **a** Immunohistochemistry of MAGE-1 expression in a neuroblastoma tumor (antibody MA454) demonstrates the heterogeneous expression of MAGE-1 in this tumor sample. **b** Visualization of MAGE-3 specific CD8<sup>+</sup> cells using labeled CD8-Ab and A1/MAGE-3-tetramers. Dot plot of peripheral blood mononuclear cells from a patient who received a vaccine containing MAGE-3.A1 peptides. Twelve percent of the CD8<sup>+</sup> cells are tetramer-positive after 2 weeks of in vitro re-stimulation with the MAGE-3.A1 peptide (EVDPIGHLY) [63]. **c** Chromium release assay using cytotoxic T lymphocyte clone EH-1 B2.C10, which recognizes peptide MAGE-3<sup>168–176</sup> presented by HLA-A1 molecules. Lysis was tested after 4 h at 37°C, as previously described [12]. Only the HLA-A1<sup>+</sup>, MAGE-3<sup>+</sup> SK-N-SH neuroblastoma cell line (*white dots*) is efficiently lysed by the CTL clone. Cell lines that are either HLA-A1 negative (IMR-32, *black dots*) or do not express gene MAGE-3 (EB81-EBV-B, *gray dots*) are not lysed

described that are recognized by CD4<sup>+</sup> and/or CD8<sup>+</sup> T cells. Detailed lists of antigen-encoding genes and of epitopes can be found at <http://www.cancerimmunity.org>.

Tables 1 and 2 summarize T cell defined antigens on a selection of the most important pediatric solid tumors. The

**Table 1** T cell defined antigens in extra-cranial pediatric solid tumors

Antigen (refs)	Neuroblastoma (%)	Rhabdomyosarc. (%)	Osteosarc. (%)	Ewing's sarc. (%)
Antigens from fusion proteins:				
PAX3/FKHR [67]	0	60 <sup>a</sup>	0	0
EWS/FLI 1 [31]	0	0	0	85
Cancer-germline genes:				
GAGE [20, 27]	82	9–16	ND	100
MAGE-1 [25, 27, 52, 54, 117, 118]	18–60	25–38	55–88	0
MAGE-2 [21, 27, 54, 118]	60–61	33–51	55–78	0
MAGE-3 [25, 27, 52, 117, 118]	33–76	35–42	52–100	28
NY-ESO-1 [54, 104, 117]	36–82	25	88	0
Overexpressed antigens:				
HER-2 [3, 41, 49, 83, 124, 139]	14	11	0–44	0
MYCN [33, 46, 130]	20–25	43–60 <sup>a</sup>	ND	ND
P53 [3, 6, 28, 91, 121, 124, 126]	84	19–67	14–27	11–43
Survivin [1, 53, 122]	47–54	ND	58	ND

The percentages indicate the proportion of tumors expressing the gene, tested with RT-PCR or IHC

*GAGE* G antigen, *HER-2* human epidermal receptor 2, *MAGE* melanoma-associated antigen, *ND* not determined, *NY-ESO-1* New York esophagus 1, *P53* protein 53, *WT-1* Wilms' tumor 1 gene

<sup>a</sup> Expression in alveolar rhabdomyosarcoma; no expression of MYCN in embryonal rhabdomyosarcoma

**Table 2** T cell defined antigens in pediatric brain tumors

Antigen (refs)	Low grade astrocytoma (%)	High grade astrocytoma (%)	Ependymoma (%)	Medulloblastoma (%)
Cancer-germline genes:				
GAGE [110]	ND	11	43	13
MAGE-1 [11, 22, 57, 102, 110]	0–33	0–100	0	9–13
MAGE-2 [57, 110]	12–18	10–11	57	18–60
MAGE-3 [22, 57, 108, 110]	18–35	20–33	0–33	13–18
NY-ESO-1 [57, 108]	0–14	0–10	ND	9
Overexpressed antigens:				
HER-2 [44, 45, 77, 111]	0–77	5–93	83	38–86
IL-13R [59, 65]	79	100	67	67–100
MYCN [2, 8, 50, 71]	ND	43	ND	5–21
P53 [58, 69, 73, 85, 132]	8–72	52–63	28–48	17–27
Survivin [60, 64, 92, 109]	37–64	80–92	100	100
WT-1 [32]	40	56	56	39
Differentiation antigens:				
Tyrosinase [22]	67	38	50	ND
Gp100 [22, 77]	33	38–47	50	ND

The percentages indicate the proportion of tumors expressing the gene, tested with RT-PCR or IHC

*GAGE* G antigen, *gp100* glycoprotein 100, *HER-2* human epidermal receptor 2, *IL* interleukin, *MAGE* melanoma-associated antigen, *ND* not determined, *NY-ESO-1* New York esophagus 1, *P53* protein 53, *WT-1* Wilms' tumor 1 gene

antigens are categorized according to the four groups mentioned in the previous paragraph. To produce a clinically relevant list, we have included only antigens of which (1) peptides recognized by T cells are identified, (2) the HLA presenting molecule is identified, (3) evidence exists that the peptide is processed and presented by tumor cells, and (4) a certain level of tumor- or tissue-specificity is reported.

Virus-encoded and artificially modified epitopes are excluded from this list. Antigens of solid tumors outside the central nervous system are shown in Table 1, and those of brain tumors in Table 2. The percentages indicate the proportions of tumors expressing the gene, tested with RT-PCR or immunohistochemistry. Original papers are only referred to if expression has been investigated in at



least ten histologically similar tumors, with no restriction as to the year of publication.

All tumors reviewed here, except neuroblastoma, also occur in adults. Most papers about antigen expression do not report whether tumor samples are derived from adults or children. Only a few papers specifically report on antigen expression in pediatric tumors [44, 54, 57, 65, 73, 85, 92]. It is important to note that the expression of a given antigen in tumors of adult patients does not guarantee that this antigen is also expressed in the tumor of that same subtype from a pediatric patient. We and others observed significant age-related differences in the expression of tumor antigens in glioblastoma samples [57, 92, 100, 120]. For some antigens we noticed important differences in the expressions reported by different groups. They can be due to the sensitivity/specificity of the techniques used (microarray, RT-PCR and immunohistochemistry), to different antibodies or primer-pairs for the same antigen, and to differently chosen cut-off points.

### Which antigens to choose for pediatric clinical trials?

Table 1 and 2 list T cell defined antigens expressed on pediatric tumors that can be used as immune target in clinical trials. So far, these antigens have primarily been used in clinical trials in adult patients with the exception of clinical trials in pediatric patients targeting the following antigens: PAX3/FKHR and EWS/FLI1 [26, 82], WT-1 (ongoing clinical trial, <http://www.clinicaltrials.gov>) and MAGE-A1 (Jacobs et al., manuscript in preparation). Choosing the best antigen in a specific immunotherapy trial depends on the individual needs for that study such as the immunogenicity of the antigen, the level of antigen expression by the tumors, the tumor-specificity of the antigen, the availability of clinical grade antigenic products, and the HLA-type of the included patients.

Mutated tumor antigens are attractive antigens for cancer immunotherapy because of their strict tumor-specificity and because of their potential resistance to immunoselection when the mutated gene product plays an important role in the oncogenic process. One drawback is that most point mutations, in contrast to chromosomal translocations, are not shared by tumors from different patients. Examples of chimeric proteins in the pediatric setting are the PAX3-FKHR, EWS-FLI 1, TEL-AML1, and BCR-ABL fusion proteins seen in alveolar rhabdomyosarcoma, Ewing's sarcoma, acute lymphatic leukemia, and chronic myeloid leukemia, respectively [18, 81, 129, 137]. For all four fusion proteins several MHC class I and class II chimeric peptides have been described that induce specific T cells and can be considered for immunotherapy [82, 136–138].

The other genetic mechanism responsible for tumor-specificity of antigens is the aberrant expression in tumor cells of genes that are silent in normal cells. When the antigens are encoded by genes that are expressed in many different tumors they are called 'shared tumor-specific antigens'. Most of the shared tumor-specific antigens are encoded by cancer-germline genes. Cancer-germline genes such as MAGE, GAGE, or LAGE/NY-ESO-1, are expressed in different types of pediatric tumors (Tables 1, 2). Numerous peptides, binding to different HLA class I and HLA class II molecules have been identified [15]. Because of their tumor-specificity and immunogenic potential, antigens encoded by cancer-germline genes have been one of the main components of antitumor vaccines tested in the clinic during the last decade [115].

Approximately 20% of all identified tumor antigens are encoded by genes that are overexpressed in cancer cells as compared to normal cells. Overexpression in this context means more antigenic peptides presented on MHC molecules at the cell surface, explaining the tumor-specificity of the T lymphocytes. As shown in Tables 1 and 2, many of the identified antigens in pediatric solid tumors are classified as overexpressed antigens. HER-2, WT-1, and MYCN are the most interesting candidates for immunotherapy since these genes are involved in cell proliferation and their overexpression plays a direct functional role in tumor progression. This role in oncogenesis implies that it is more difficult for the tumor to escape immune attack through downregulation of antigen expression. The absence of autoimmune tissue damage in cancer patients with HER-2, WT-1, or MYCN specific CTLs suggests that these antigens can be safely used as immunotherapeutic target [5, 7, 48].

With the observation that tumor-specific CTL clones derived from melanoma patients could also recognize normal melanocytes it became obvious that natural tolerance to differentiation antigens was incomplete [4]. Gp100 and tyrosinase are the only differentiation antigens expressed in pediatric tumors for which T cell specific peptides are identified (Table 2). Autoimmunity can be a side effect when differentiation antigens are used for vaccination. Since gp100 and tyrosinase are expressed in normal melanocytes, it is possible that pediatric patients will develop vitiligo when these antigens are used in a vaccine [56, 127].

For safety concern, the target antigens used in pediatric clinical trials should be strictly tumor-specific. If such an antigen is not available, the normal tissue expressing the antigen must be dispensable, to avoid serious autoimmune toxicity. Finally, it is probably preferable to use combinations of antigens to decrease the probability of *in vivo* selection of antigen-negative tumor cells.

## Conclusion

Immunotherapy against cancer is a field of growing interest. Most therapies are still experimental and focus on adult patients. However, the first immunotherapeutic trials for pediatric cancer patients have been published, and more are ongoing. These novel trials aim at stimulating both humoral and cellular anti-tumor immune responses. The identification of many tumor-associated antigens, including for most pediatric solid tumor types, should facilitate this clinical endeavor.

**Acknowledgments** This work is supported by grants from *The Quality of Life Gala* and *Stichting (Vrienden van het) Kinderoncologisch Centrum Zuid-Oost Nederland* and grants from the EU projects Cancerimmunotherapy (#LSHC-CT-2006-518234) and DC-Thera (#LSHB-CT-2004-512074).

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

## References

- Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. *Lancet* 351:882–883
- Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE (2002) MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. *Arch Pathol Lab Med* 126:540–544
- Amir G, Issakov J, Meller I, Sucher E, Peyser A, Cohen IJ, Yaniv I, Ben Arush MW, Tavori U, Kollender Y, Ron N, Peylan-Ramu N (2002) Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome. *Hum Pathol* 33:170–174
- Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G (1993) Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. *J Exp Med* 177:989–998
- Asemissen AM, Keilholz U, Tenzer S, Muller M, Walter S, Stevanovic S, Schild H, Letsch A, Thiel E, Rammensee HG, Scheibenbogen C (2006) Identification of a highly immunogenic HLA-A\*01-binding T cell epitope of WT1. *Clin Cancer Res* 12:7476–7482
- Ayan I, Dogan O, Kebudi R, Bavbek B, Alatli C, Dervisoglu S, Disci R, Demiryont M (1997) Immunohistochemical detection of p53 protein in rhabdomyosarcoma: association with clinicopathological features and outcome. *J Pediatr Hematol Oncol* 19:48–53
- Baxevasis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M (2006) Immunogenic HER-2/neu peptides as tumor vaccines. *Cancer Immunol Immunother* 55:85–95
- Bayani J, Zielenska M, Marrano P, Kwan Ng Y, Taylor MD, Jay V, Rutka JT, Squire JA (2000) Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. *J Neurosurg* 93:437–448
- Biagi E, Bollard C, Rousseau R, Brenner M (2003) Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives. *J Biomed Biotechnol* 2003:13–24
- Bodey B, Bodey B Jr, Siegel SE (1995) Immunophenotypic characterization of infiltrating polynuclear and mononuclear cells in childhood brain tumors. *Mod Pathol* 8:333–338
- Bodey B, Siegel SE, Kaiser HE (2002) MAGE-1, a cancer/testis-antigen, expression in childhood astrocytomas as an indicator of tumor progression. *In Vivo* 16:583–588
- Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. *J Exp Med* 152:1184–1193
- Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. *Annu Rev Immunol* 12:337–365
- Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. *Immunol Today* 18:267–268
- Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. *Annu Rev Immunol* 24:175–208
- Bowman L, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, Leimig T, Coustan-Smith E, Campana D, Jenkins J, Woods D, Kitchingman G, Vanin E, Brenner M (1998) IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. *Blood* 92:1941–1949
- Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. *Science* 224:1121–1124
- Browett PJ, Cooke HM, Secker-Walker LM, Norton JD (1989) Chromosome 22 breakpoints in variant Philadelphia translocations and Philadelphia-negative chronic myeloid leukemia. *Cancer Genet Cytogenet* 37:169–177
- Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, Maixner W, Downie P, Hassall TE, Tang ML, Ashley DM (2004) Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. *Neuro Oncol* 6:236–246
- Cheung IY, Cheung NK (1997) Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. *Clin Cancer Res* 3:821–826
- Cheung IY, Cheung NK (2001) Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. *Med Pediatr Oncol* 36:210–212
- Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL, Hoon DS (1997) Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. *Am J Pathol* 150:2143–2152
- Cooper LJ (2008) Adoptive cellular immunotherapy for childhood malignancies. *Bone Marrow Transplant* 41:183–192
- Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM (2002) Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. *J Immunol* 169:1829–1836
- Corrias MV, Scaruffi P, Occhino M, De Bernardi B, Tonini GP, Pistoia V (1996) Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. *Int J Cancer* 69:403–407
- Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL (2002) Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. *Med Pediatr Oncol* 38:158–164

27. Dalerba P, Frascella E, Macino B, Mandruzzato S, Zambon A, Rosolen A, Carli M, Ninfo V, Zanovello P (2001) *MAGE*, *BAGE* and *GAGE* gene expression in human rhabdomyosarcomas. *Int J Cancer* 93:85–90
28. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindan FJ, Healey JH, Ladanyi M (2000) Prognostic impact of *P53* status in Ewing sarcoma. *Cancer* 89:783–792
29. De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JE, Plets C, Sciort R, Van Gool SW (2004) Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. *J Neurosurg* 100:492–497
30. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciort R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. *Clin Cancer Res* 14:3098–3104
31. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G (1992) Gene fusion with an *ETS* DNA-binding domain caused by chromosome translocation in human tumours. *Nature* 359:162–165
32. Dennis SL, Manji SS, Carrington DP, Scarcella DL, Ashley DM, Smith PJ, Algar EM (2002) Expression and mutation analysis of the *Wilms'* tumor 1 gene in human neural tumors. *Int J Cancer* 97:713–715
33. Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J (1994) *MYCN* gene amplification in rhabdomyosarcoma. *Cancer* 73:2231–2237
34. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. *Nat Immunol* 3:991–998
35. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW (2002) Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. *Immunol Rev* 188:136–146
36. Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. *N Engl J Med* 348:1681–1691
37. Finn OJ (2003) Cancer vaccines: between the idea and the reality. *Nat Rev Immunol* 3:630–641
38. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of *HER-2/neu* protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. *J Exp Med* 181:2109–2117
39. Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. *Cancer Res* 13:835–837
40. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM (1997) A phase I/II trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. *Cancer* 80:317–333
41. Gambini C, Sementa AR, Boni L, Marino CE, Croce M, Negri F, Pistoia V, Ferrini S, Corrias MV (2003) Expression of *HER2/neu* is uncommon in human neuroblastoma and is unrelated to tumor progression. *Cancer Immunol Immunother* 52:116–120
42. Gandhi MK, Tellam JT, Khanna R (2004) Epstein-Barr virus-associated Hodgkin's lymphoma. *Br J Haematol* 125:267–281
43. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. *Cancer Res* 61:8513–8519
44. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J (1997) Prognostic significance of *HER2* and *HER4* coexpression in childhood medulloblastoma. *Cancer Res* 57:3272–3280
45. Haapasalo H, Hyytinen E, Sallinen P, Helin H, Kallioniemi OP, Isola J (1996) *c-erbB-2* in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. *Br J Cancer* 73:620–623
46. Hachitanda Y, Toyoshima S, Akazawa K, Tsuneyoshi M (1998) *N-myc* gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features. *Mod Pathol* 11:1222–1227
47. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM (2000) Eradication of established tumors by *CD8+* T cell adoptive immunotherapy. *Immunity* 13:265–276
48. Himoudi N, Yan M, Papanastasiou A, Anderson J (2008) *MYCN* as a target for cancer immunotherapy. *Cancer Immunol Immunother* 57:693–700
49. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT (2004) Cell surface expression of epidermal growth factor receptor and *Her-2* with nuclear expression of *Her-4* in primary osteosarcoma. *Cancer Res* 64:2047–2053
50. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK (2001) Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. *Lab Invest* 81:717–723
51. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of *CD4(+)* T cells in the anti-tumor immune response. *J Exp Med* 188:2357–2368
52. Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T (1996) *MAGE-1* and *MAGE-3* or *-6* expression in neuroblastoma-related pediatric solid tumors. *Int J Cancer* 69:375–380
53. Ito R, Asami S, Motohashi S, Ootsuka S, Yamaguchi Y, Chin M, Shichino H, Yoshida Y, Nemoto N, Mugishima H, Suzuki T (2005) Significance of survivin mRNA expression in prognosis of neuroblastoma. *Biol Pharm Bull* 28:565–568
54. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, van de Rakt MW, Figdor CG, Adema GJ, Hoogerbrugge PM, Coulie PG, de Vries IJ (2007) Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. *Int J Cancer* 120:67–74
55. Jacobs JF, Hoogerbrugge PM, de Rakt MW, Aarntzen EH, Figdor CG, Adema GJ, de Vries IJ (2007) Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. *Pediatr Blood Cancer* 49:924–927
56. Jacobs JF, Aarntzen EH, Sibelt LA, Blokk WA, Boullart AC, Geritsen MJ, Hoogerbrugge PM, Figdor CG, Adema GJ, Punt CJ, de Vries IJ (2008) Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. *Cancer Immunol Immunother* 58(1):145–151. doi:10.1007/s00262-008-0506-5
57. Jacobs JF, Grauer OM, Brasseur F, Hoogerbrugge PM, Wesseling P, Gidding CE, van de Rakt MW, Figdor CG, Coulie PG, de Vries IJ, Adema GJ (2008) Selective cancer-germline gene expression in pediatric brain tumors. *J Neurooncol* 88(3):273–280
58. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson AD (1992) Prognostic implications of *p53* protein, epidermal growth factor receptor, and *Ki-67* labelling in brain tumours. *Br J Cancer* 66:373–385
59. Joshi BH, Leland P, Puri RK (2003) Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein. *Croat Med J* 44:455–462
60. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K (2003) Expression of survivin in



- astrocytic tumors: correlation with malignant grade and prognosis. *Cancer* 97:1077–1083
61. Kalos M (2003) Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. *Vaccine* 21:781–786
  62. Kalwak K, Ussowicz M, Gorczyńska E, Turkiewicz D, Toporski J, Dobaczewski G, Latos-Grazyska E, Ryczan R, Noworolska-Sauren D, Chybicka A (2003) Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors. *J Interferon Cytokine Res* 23:173–181
  63. Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethe B, Connerotte T, Corbiere V, Demoitte MA, Lienard D, Dreno B, Velu T, Boon T, Coulie PG (2003) Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. *J Immunol* 171:4898–4904
  64. Katoh M, Wilmotte R, Belkouch MC, de Tribolet N, Pizzolato G, Dietrich PY (2003) Survivin in brain tumors: an attractive target for immunotherapy. *J Neurooncol* 64:71–76
  65. Kawakami M, Kawakami K, Takahashi S, Abe M, Puri RK (2004) Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. *Cancer* 101:1036–1042
  66. Kershaw MH, Trapani JA, Smyth MJ (1995) Cytotoxic lymphocytes redirecting the cell-mediated immune response for the therapy of cancer. *Ther Immunol* 2:173–181
  67. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM, Meltzer PS (1999) cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. *Proc Natl Acad Sci USA* 96:13264–13269
  68. Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D (2004) IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. *Blood Cells Mol Dis* 33:261–266
  69. Korshunov A, Golanov A, Timirgazy V (2002) Immunohistochemical markers for prognosis of ependymal neoplasms. *J Neurooncol* 58:255–270
  70. Kuroki M, Shibaguchi H, Imakiire T, Uno K, Shirota K, Higuchi T, Shitama T, Yamada H, Hirose Y, Nagata A (2003) Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens. *Anticancer Res* 23:4377–4381
  71. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW (2004) Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. *Clin Cancer Res* 10:5482–5493
  72. Lampson LA (2003) Brain tumor immunotherapy: an immunologist's perspective. *J Neurooncol* 64:3–11
  73. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW (1994) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. *Oncogene* 9:949–954
  74. Larin SS, Georgiev GP, Kiselev SL (2004) Gene transfer approaches in cancer immunotherapy. *Gene Ther* 11(Suppl 1):S18–S25
  75. Leung W, Hudson MM, Strickland DK, Phipps S, Srivastava DK, Ribeiro RC, Rubnitz JE, Sandlund JT, Kun LE, Bowman LC, Razzouk BI, Mathew P, Shearer P, Evans WE, Pui CH (2000) Late effects of treatment in survivors of childhood acute myeloid leukemia. *J Clin Oncol* 18:3273–3279
  76. Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS (1999) Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. *J Natl Cancer Inst* 91:1051–1058
  77. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS (2004) HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. *Cancer Res* 64:4980–4986
  78. Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. *Nat Rev Immunol* 7:329–339
  79. Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA (2000) Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. *Med Pediatr Oncol* 35:641–646
  80. Lu S, Wang S, Grimes-Serrano JM (2008) Current progress of DNA vaccine studies in humans. *Expert Rev Vaccines* 7:175–191
  81. Mackall C, Berzofsky J, Helman LJ (2000) Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. *Clin Orthop Relat Res* 373:25–31
  82. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ (2008) A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. *Clin Cancer Res* 14:4850–4858
  83. Mark HF, Brown S, Sun CL, Samy M, Afify A (1998) Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. *Pathobiology* 66:59–63
  84. Miller JS, Soignier Y, Panoskaltis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood* 105:3051–3057
  85. Miralbell R, Tolnay M, Bieri S, Probst A, Sappino AP, Berchtold W, Pepper MS, Pizzolato G (1999) Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density. *J Neurooncol* 45:103–110
  86. Modak S, Cheung NK (2005) Antibody-based targeted radiation to pediatric tumors. *J Nucl Med* 46(Suppl 1):157S–163S
  87. Modak S, Cheung NK (2007) Disialoganglioside directed immunotherapy of neuroblastoma. *Cancer Invest* 25:67–77
  88. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukowski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS (1994) Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. *J Clin Oncol* 12:184–193
  89. Nakachi K, Hayashi T, Imai K, Kusunoki Y (2004) Perspectives on cancer immuno-epidemiology. *Cancer Sci* 95:921–929
  90. Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. *Cancer Immunol Immunother* 54:187–207
  91. Oda Y, Wehrmann B, Radig K, Walter H, Rose I, Neumann W, Roessner A (1995) Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. *Gen Diagn Pathol* 141:97–103
  92. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF (2008) Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. *J Neurooncol* 88(3):245–250
  93. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. *J Exp Med* 187:693–702
  94. Parney IF, Chang LJ (2003) Cancer immunogene therapy: a review. *J Biomed Sci* 10:37–43
  95. Pavlenko M, Leder C, Pisa P (2005) Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. *Expert Rev Vaccines* 4:315–327

96. Penn I (1988) Tumors of the immunocompromised patient. *Annu Rev Med* 39:63–73
97. Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA (2003) Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. *Blood* 101:649–654
98. Porter DL, Antin JH (1999) The graft-versus-leukemia effects of allogeneic cell therapy. *Annu Rev Med* 50:369–386
99. Ransohoff RM, Kivisakk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. *Nat Rev Immunol* 3:569–581
100. Rickert CH, Strater R, Kaatsch P, Wassmann H, Jurgens H, Dockhorn-Dworniczak B, Paulus W (2001) Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. *Am J Pathol* 158:1525–1532
101. Ridgway D (2003) The first 1000 dendritic cell vaccinees. *Cancer Invest* 21:873–886
102. Rimoldi D, Romero P, Carrel S (1993) The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. *Int J Cancer* 54:527–528
103. Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G (1992) Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. *Cancer Immunol Immunother* 34:241–251
104. Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C (2003) Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. *Cancer Res* 63:6948–6955
105. Rowlinson-Busza G, Epenetos AA (1992) Targeted delivery of biologic and other antineoplastic agents. *Curr Opin Oncol* 4:1142–1148
106. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A (2005) Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. *Curr Opin Immunol* 17:211–217
107. Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R (2007) Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. *J Immunother* 30:227–233
108. Sahin U, Koslowski M, Tureci O, Eberle T, Zwick C, Romeike B, Moringlane JR, Schwachheimer K, Feiden W, Pfreundschuh M (2000) Expression of cancer testis genes in human brain tumors. *Clin Cancer Res* 6:3916–3922
109. Sasaki T, Lopes MB, Hankins GR, Helm GA (2002) Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. *Acta Neuropathol (Berl)* 104:105–109
110. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM (1999) Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. *Clin Cancer Res* 5:335–341
111. Schwachheimer K, Lauffle RM, Schmahl W, Knodlseder M, Fischer H, Hoffer H (1994) Expression of neu/c-erbB-2 in human brain tumors. *Hum Pathol* 25:772–780
112. Seibel NL, Dinndorf PA, Bauer M, Sondel PM, Hammond GD, Reaman GH (1994) Phase I study of tumor necrosis factor- $\alpha$  and actinomycin D in pediatric patients with cancer: a Children's Cancer Group study. *J Immunother Emphasis Tumor Immunol* 16:125–131
113. Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M (2006) Natural killer T cell-mediated antitumor immune responses and their clinical applications. *Cancer Sci* 97:807–812
114. Serraino D, Piselli P, Angeletti C, Scuderi M, Ippolito G, Capobianchi MR (2005) Infection with Epstein-Barr virus and cancer: an epidemiological review. *J Biol Regul Homeost Agents* 19:63–70
115. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. *Nat Rev Cancer* 5:615–625
116. Sinkovics JG, Horvath JC (2000) Vaccination against human cancers (review). *Int J Oncol* 16:81–96
117. Soling A, Schurr P, Berthold F (1999) Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. *Anticancer Res* 19:2205–2209
118. Sudo T, Kuramoto T, Komiya S, Inoue A, Itoh K (1997) Expression of MAGE genes in osteosarcoma. *J Orthop Res* 15:128–132
119. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. *J Clin Invest* 117:1137–1146
120. Szybka M, Bartkowiak J, Zakrzewski K, Polis L, Liberski P, Kordek R (2003) Microsatellite instability and expression of DNA mismatch repair genes in malignant astrocytic tumors from adult and pediatric patients. *Clin Neuropathol* 22:180–186
121. Takahashi Y, Oda Y, Kawaguchi K, Tamiya S, Yamamoto H, Suita S, Tsuneyoshi M (2004) Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. *Mod Pathol* 17:660–669
122. Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR (2003) Survivin expression in human osteosarcoma is a marker for survival. *Eur J Surg Oncol* 29:379–382
123. Truitt RL, Piaskowski V, Kirchner P, McOlash L, Camitta BM, Casper JT (1992) Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial. *J Immunother* 11:274–285
124. Tsai JY, Aviv H, Benevenia J, Chang VT, Patterson F, Aisner S, Hameed M (2004) HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. *Cancer Invest* 22:16–24
125. Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozaawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T, Yamashita T, Sato N (2006) Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8–5. *Cancer Sci* 97:1374–1380
126. Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J (2001) p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. *Am J Pathol* 158:2067–2077
127. Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN (2006) Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. *Adv Immunol* 90:215–241
128. Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL (1995) Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. *Cancer Immunol Immunother* 41:29–36
129. van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA (2006) Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. *Cancer Res* 66:1818–1823
130. van Noesel MM, Versteeg R (2004) Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. *Gene* 325:1–15
131. Velders MP, Markiewicz MA, Eiben GL, Kast WM (2003) CD4+ T cell matters in tumor immunity. *Int Rev Immunol* 22:113–140
132. Vital A, Loiseau H, Kantor G, Daucourt V, Chene G, Cohadon F, Rougier A, Rivel J, Vital C (1998) p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up. *Pathol Res Pract* 194:831–836
133. Vlk V, Eckschlager T, Kavan P, Kabickova E, Koutecky J, Sobota V, Bubenik J, Pospisilova D (2000) Clinical ineffectiveness

- of IL-2 and/or IFN alpha administration after autologous PBSC transplantation in pediatric oncological patients. *Pediatr Hematol Oncol* 17:31–44
134. Ward S, Casey D, Labarthe MC, Whelan M, Dalgleish A, Pandha H, Todryk S (2002) Immunotherapeutic potential of whole tumour cells. *Cancer Immunol Immunother* 51:351–357
135. Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS (1998) Second cancers following pediatric Hodgkin's disease. *J Clin Oncol* 16:536–544
136. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. *J Clin Invest* 101:2290–2296
137. Yotnda P, Garcia F, Peuchmaur M, Grandchamp B, Duval M, Lemonnier F, Vilmer E, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. *J Clin Invest* 102:455–462
138. Yun C, Senju S, Fujita H, Tsuji Y, Irie A, Matsushita S, Nishimura Y (1999) Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. *Tissue Antigens* 54:153–161
139. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE (2003) Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. *J Pediatr Hematol Oncol* 25:27–32